Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for Daniel Van Roy�
303.08
-8.60 (-2.76%)
After Hours: 306.00 +2.92 (0.96%)
Apr 23, 6:21PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 301.87 - 312.88
52 week 206.30 - 352.49
Open 312.36
Vol / Avg. 609,800.00/1.15M
Mkt cap 30.29B
P/E 80.17
Div/yield     -
EPS 3.78
Shares 99.93M
Beta 0.84
Inst. own 77%
May 8, 2014
Q1 2014 Regeneron Pharmaceuticals Earnings Release - 9:30AM EDT - Add to calendar
May 8, 2014
Q1 2014 Regeneron Pharmaceuticals Earnings Conference Call - 8:30AM EDT - Add to calendar
Mar 31, 2014
Sanofi SA and Regeneron Pharmaceuticals Inc IR Thematic Conference Call on Alirocumab - Webcast
Mar 30, 2014
Regeneron Pharmaceuticals at American College of Cardiology (ACC) 2014: 63rd Annual Scientific Session & Expo
Mar 11, 2014
Regeneron Pharmaceuticals at Barclays Healthcare Conference
Mar 3, 2014
Regeneron Pharmaceuticals at Cowen Health Care Conference
Feb 25, 2014
Regeneron Pharmaceuticals at RBC Capital Markets Healthcare Conference
Feb 11, 2014
Q4 2013 Regeneron Pharmaceuticals Earnings Release
Feb 11, 2014
Q4 2013 Regeneron Pharmaceuticals Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 15.86% 20.16%
Operating margin 34.74% 36.11%
EBITD margin - 38.07%
Return on average assets 13.89% 16.87%
Return on average equity 21.32% 26.54%
Employees 2,340 -
CDP Score - -

Address

777 Old Saw Mill River Road
TARRYTOWN, NY 10591-6707
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 83
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 49
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 54
Bio & Compensation  - Reuters
Daniel P. Van Plew Senior Vice President, General Manager - Industrial Operations and Product Supply
Age: 40
Bio & Compensation  - Reuters
Murray A. Goldberg Senior Vice President - Administration, Assistant Secretary
Age: 68
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 56
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Senior Vice President - Research and Development Sciences
Age: 56
Bio & Compensation  - Reuters
Robert J. Terifay Senior Vice President - Commercial
Age: 53
Bio & Compensation  - Reuters
George D. Yancopoulos M.D., Ph.D. Chief Scientific Officer and President - Regeneron Laboratories, Director
Age: 53
Bio & Compensation  - Reuters